Evaluation of [(11)C]N-Methyl Lansoprazole As a Radiopharmaceutical for PET Imaging of Tau Neurofibrillary Tangles

Overview

Journal ACS Med Chem Lett

Publisher American Chemical Society

Specialty Chemistry

Date 2014 Jun 6

PMID 24900410

Citations 21

Authors

Xia Shao

Garrett M Carpenter

Timothy J Desmond

Phillip Sherman

Carole A Quesada

Maria Fawaz

Allen F Brooks

Michael R Kilbourn

Roger L Albin

Kirk A Frey

Peter J H Scott

Affiliations

Soon will be listed here.

Abstract

[(11)C]N-Methyl lansoprazole ([(11)C]NML, 3) was synthesized and evaluated as a radiopharmaceutical for quantifying tau neurofibrillary tangle (NFT) burden using positron emission tomography (PET) imaging. [(11)C]NML was synthesized from commercially available lansoprazole in 4.6% radiochemical yield (noncorrected RCY, based upon [(11)C]MeI), 99% radiochemical purity, and 16095 Ci/mmol specific activity (n = 5). Log P was determined to be 2.18. A lack of brain uptake in rodent microPET imaging revealed [(11)C]NML to be a substrate for the rodent permeability-glycoprotein 1 (PGP) transporter, but this could be overcome by pretreating with cyclosporin A to block the PGP. Contrastingly, [(11)C]NML was not found to be a substrate for the primate PGP, and microPET imaging in rhesus revealed [(11)C]NML uptake in the healthy primate brain of ∼1600 nCi/cc maximum at 3 min followed by rapid egress to 500 nCi/cc. Comparative autoradiography between wild-type rats and transgenic rats expressing human tau (hTau +/+) revealed 12% higher uptake of [(11)C]NML in the cortex of brains expressing human tau. Further autoradiography with tau positive brain samples from progressive supranuclear palsy (PSP) patients revealed colocalization of [(11)C]NML with tau NFTs identified using modified Bielschowsky staining. Finally, saturation binding experiments with heparin-induced tau confirmed K d and Bmax values of [(11)C]NML as 700 pM and 0.214 fmol/μg, respectively.

Citing Articles

Strategies of positron emission tomography (PET) tracer development for imaging of tau and α-synuclein in neurodegenerative disorders.

Mekala S, Wu Y, Li Y RSC Med Chem. 2024; .

PMID: 39678127 PMC: 11638850. DOI: 10.1039/d4md00576g.

The Sensitivity of Tau Tracers for the Discrimination of Alzheimer's Disease Patients and Healthy Controls by PET.

Mohammadi Z, Alizadeh H, Marton J, Cumming P Biomolecules. 2023; 13(2).

PMID: 36830659 PMC: 9953528. DOI: 10.3390/biom13020290.

Positron Emission Tomography in Animal Models of Tauopathies.

Cao L, Kong Y, Ji B, Ren Y, Guan Y, Ni R Front Aging Neurosci. 2022; 13:761913.

PMID: 35082657 PMC: 8784812. DOI: 10.3389/fnagi.2021.761913.

Molecular Imaging of Fluorinated Probes for Tau Protein and Amyloid-β Detection.

Yeo S, Shepelytskyi Y, Grynko V, Albert M Molecules. 2020; 25(15).

PMID: 32731418 PMC: 7435578. DOI: 10.3390/molecules25153413.

Evaluation of [F]--Methyl lansoprazole as a Tau PET Imaging Agent in First-in-Human Studies.

Kramer V, Brooks A, Haeger A, Kuljis R, Rafique W, Koeppe R ACS Chem Neurosci. 2020; 11(3):427-435.

PMID: 31898886 PMC: 7035908. DOI: 10.1021/acschemneuro.9b00639.

References

Giannakopoulos P, Herrmann F, Bussiere T, Bouras C, Kovari E, Perl D . Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology. 2003; 60(9):1495-500. DOI: 10.1212/01.wnl.0000063311.58879.01. View

Nordberg A . PET imaging of amyloid in Alzheimer's disease. Lancet Neurol. 2004; 3(9):519-27. DOI: 10.1016/S1474-4422(04)00853-1. View

Wolk D, Grachev I, Buckley C, Kazi H, Grady M, Trojanowski J . Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol. 2011; 68(11):1398-403. PMC: 4532383. DOI: 10.1001/archneurol.2011.153. View

Herholz K, Ebmeier K . Clinical amyloid imaging in Alzheimer's disease. Lancet Neurol. 2011; 10(7):667-70. DOI: 10.1016/S1474-4422(11)70123-5. View

Pearce R, Rodrigues A, Goldstein J, Parkinson A . Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther. 1996; 277(2):805-16. View

Rojo L, Alzate-Morales J, Saavedra I, Davies P, Maccioni R . Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease. J Alzheimers Dis. 2010; 19(2):573-89. PMC: 2951486. DOI: 10.3233/JAD-2010-1262. View

Williams D, Holton J, Strand C, Pittman A, de Silva R, Lees A . Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. Brain. 2007; 130(Pt 6):1566-76. DOI: 10.1093/brain/awm104. View

Karran E, Mercken M, De Strooper B . The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011; 10(9):698-712. DOI: 10.1038/nrd3505. View

Okamura N, Suemoto T, Furumoto S, Suzuki M, Shimadzu H, Akatsu H . Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. J Neurosci. 2005; 25(47):10857-62. PMC: 6725872. DOI: 10.1523/JNEUROSCI.1738-05.2005. View

10.

Zhang W, Arteaga J, Cashion D, Chen G, Gangadharmath U, Gomez L . A highly selective and specific PET tracer for imaging of tau pathologies. J Alzheimers Dis. 2012; 31(3):601-12. DOI: 10.3233/JAD-2012-120712. View

11.

Rowe C, Ackerman U, Browne W, Mulligan R, Pike K, OKeefe G . Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008; 7(2):129-35. DOI: 10.1016/S1474-4422(08)70001-2. View

12.

Nordberg A . Amyloid imaging in Alzheimer's disease. Neuropsychologia. 2008; 46(6):1636-41. DOI: 10.1016/j.neuropsychologia.2008.03.020. View

13.

Clark C, Schneider J, Bedell B, Beach T, Bilker W, Mintun M . Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011; 305(3):275-83. PMC: 7041965. DOI: 10.1001/jama.2010.2008. View

14.

Shin J, Cho Y, Sachs G . Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors. J Am Chem Soc. 2004; 126(25):7800-11. DOI: 10.1021/ja049607w. View

15.

Wong D, Rosenberg P, Zhou Y, Kumar A, Raymont V, Ravert H . In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010; 51(6):913-20. PMC: 3101877. DOI: 10.2967/jnumed.109.069088. View

16.

Blanckaert P, Burvenich I, Staelens S, De Bruyne S, Moerman L, Wyffels L . Effect of cyclosporin A administration on the biodistribution and multipinhole muSPECT imaging of [123I]R91150 in rodent brain. Eur J Nucl Med Mol Imaging. 2008; 36(3):446-53. DOI: 10.1007/s00259-008-0968-x. View

17.

Karol M, MACHINIST J, Cavanaugh J . Lansoprazole pharmacokinetics in subjects with various degrees of kidney function. Clin Pharmacol Ther. 1997; 61(4):450-8. DOI: 10.1016/S0009-9236(97)90195-8. View

18.

Perl D . Neuropathology of Alzheimer's disease. Mt Sinai J Med. 2010; 77(1):32-42. PMC: 2918894. DOI: 10.1002/msj.20157. View

19.

Hardy J, Selkoe D . The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002; 297(5580):353-6. DOI: 10.1126/science.1072994. View

20.

Sarkadi B, Homolya L, Szakacs G, Varadi A . Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev. 2006; 86(4):1179-236. DOI: 10.1152/physrev.00037.2005. View